Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (2)
  • Open Access

    ARTICLE

    Discovery and Characterization of Novel IKZF1/3 Glue Degraders against Multiple Hematological Cancer Cell Lines

    Ting Wei1,2,#, Pengli Wei2,3,#, Yalei Wang1,2, Yaqiu Mao2,3, Jian Yan2, Xiaotong Hu2, Zhenze Qi2, Xu Cai2, Changkai Jia2, Zhiyuan Zhao2, Bingkun Li2, Min Qiao2, Yaxin Zou2,3, Tingting Yang4, Shiyang Sun2, Xuesong Feng3, Pengyun Li2,*, Hongzhou Shang1,*, Zhibing Zheng2

    Oncology Research, Vol.33, No.10, pp. 2981-3006, 2025, DOI:10.32604/or.2025.065123 - 26 September 2025

    Abstract Objectives: Immunomodulatory drugs (IMiDs), functioning as molecular glue degraders, have been approved for treating various hematological malignancies; however, the inevitable acquired drug resistance resulting from their skeletal similarity and hematological toxicities poses significant obstacles to their clinical treatment. The study aimed to develop degraders with potent efficiency and low toxicity. Methods: Phenotypic profiling, elaborate structure-activity relationships (SAR), rational drug design and degradation profiles investigations, quantitative proteomics analysis and cell-based functional studies, and pharmacokinetic studies were conducted to develop more potent degraders. Results: This study developed novel CRBN-binding moieties through methylene deletion in lenalidomide’s isoindole core. Lead… More > Graphic Abstract

    Discovery and Characterization of Novel IKZF1/3 Glue Degraders against Multiple Hematological Cancer Cell Lines

  • Open Access

    REVIEW

    Development of PROTACS degrading KRAS and SOS1

    GERHARD HAMILTON*, MARIE-THERESE EGGERSTORFER, SANDRA STICKLER

    Oncology Research, Vol.32, No.8, pp. 1257-1264, 2024, DOI:10.32604/or.2024.051653 - 17 July 2024

    Abstract The Kirsten rat sarcoma virus—son of sevenless 1 (KRAS-SOS1) axis drives tumor growth preferentially in pancreatic, colon, and lung cancer. Now, KRAS G12C mutated tumors can be successfully treated with inhibitors that covalently block the cysteine of the switch II binding pocket of KRAS. However, the range of other KRAS mutations is not amenable to treatment and the G12C-directed agents Sotorasib and Adragrasib show a response rate of only approximately 40%, lasting for a mean period of 8 months. One approach to increase the efficacy of inhibitors is their inclusion into proteolysis-targeting chimeras (PROTACs), which… More > Graphic Abstract

    Development of PROTACS degrading KRAS and SOS1

Displaying 1-10 on page 1 of 2. Per Page